IMM-101

IMM-101 is an immunomodulatory drug that is being studied to see if it is useful in chemotherapy.[1] It consists of heat-killed Mycobacterium obuense bacteria. It may have relatively few side effects compared to other drugs.[2][3]

References
  1. Dalgleish, AG; Stebbing, J; Adamson, DJ; Arif, SS; Bidoli, P; Chang, D; Cheeseman, S; Diaz-Beveridge, R; Fernandez-Martos, C; Glynne-Jones, R; Granetto, C; Massuti, B; McAdam, K; McDermott, R; Martín, AJ; Papamichael, D; Pazo-Cid, R; Vieitez, JM; Zaniboni, A; Carroll, KJ; Wagle, S; Gaya, A; Mudan, SS (6 September 2016). "Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer". British Journal of Cancer. 115 (7): 789–96. doi:10.1038/bjc.2016.271. PMC 5046215. PMID 27599039.
  2. "New drug 'wakes up' immune system to fight one of deadliest cancers".
  3. "A trial looking at a new type of immunotherapy for cancer of the pancreas that can't be removed with surgery".
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.